Guadagnuolo V, Papayannidis C, Iacobucci I, et al. SIRPB1: biomarker of response to 5-azacitidine treatment in MDS and AML patients. EHA 2017, abstract E1201.
Resultaten Admiral-studie: EMA-goedkeuring gilteritinib AML met FLT3-mutatie
dec 2019 | Leukemie